No Data
No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Jilin Aodong Pharmaceutical Group (000623.SZ): The holding subsidiary has received the notification of compliance inspection for Pharmaceutical GMP.
On February 10, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that its holding subsidiary, Jilin Aodong Yanbian Pharmaceutical Co., Ltd., received the "Pharmaceutical GMP Compliance Inspection Notification" approved and issued by the Jilin Provincial Drug Administration. This successful passing of the Pharmaceutical GMP compliance inspection by Yanbian Pharmaceutical indicates that the mentioned production scope meets the requirements of the "Good Manufacturing Practice for Pharmaceutical Production."
Jilin Aodong Pharmaceutical Group (000623.SZ): has cumulatively repurchased 1.71% of its shares.
On February 5, Glonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that as of January 31, 2025, the company had cumulatively repurchased 20,443,900 shares of its stock through a dedicated securities account via centralized bidding Trade, accounting for 1.71% of the total share capital of 1,195,895,387 shares as of January 31, 2025. The highest Fill Price was 19.21 yuan per share, the lowest Fill Price was 15.80 yuan per share, and the total amount paid was 0.369 billion yuan (excluding transaction fees).
Jilin Aodong Pharmaceutical Group (000623.SZ): Amlodipine Atorvastatin Calcium Tablets have obtained approval for the pharmaceutical supplementary application.
Jilin Aodong Pharmaceutical Group (000623.SZ) announced that recently, the company's holding subsidiary Jilin Aodong Pharmaceutical Group Yanji Branch...
Many Still Looking Away From Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)
Jilin Aodong Pharmaceutical Group (000623.SZ): Taonan Pharmaceutical has obtained the registration certificate for Lenvatinib Mesylate capsules.
On January 13, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that recently, its controlling subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd. (referred to as "Taonan Pharmaceutical"), received two "Drug Registration Certificates" from the National Medical Products Administration for Lenvatinib Mesylate Capsules with specifications of 10 mg and 4 mg. Lenvatinib Mesylate Capsules are indicated for: 1. Patients with unresectable hepatocellular carcinoma who have not received any systemic treatment before. The key research on Lenvatinib Mesylate excluded patients with hepatocellular carcinoma who could receive acceptable local therapy, and there is currently no available research data for these patients.
